Skip to content
The People's CodeSearch
Menu

S. 694 · Senate bill · 119th Congress

PLASMA Act

  1. Introduced
  2. In committeeFinance
  3. Passed the Senate (not yet)
  4. Passed the House (not yet)
  5. Law (not yet)

What it would change

About this text

Text: , (the only version so far)

Official text on Congress.gov

This bill would change existing law, but we couldn't automatically match its changes to the Code.

Its own words follow, each change we couldn't place marked where it stands.

3 changes we couldn't place in the Code
  • social security act § 1860D-14C(g)(4) — it changes a law that isn't arranged into the US Code, or doesn't say where in the Code In the bill’s text
  • social security act § 1860D-14C(g)(4) — it changes a law that isn't arranged into the US Code, or doesn't say where in the Code In the bill’s text
  • social security act § 1860D-14C(g)(4) — it changes a law that isn't arranged into the US Code, or doesn't say where in the Code In the bill’s text

Sec. 1. Short title This Act may be cited as the Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act.

Sec. 2. Phase-in for plasma-derived products under manufacturer discount program Section 1860D–14C(g)(4) of the Social Security Act (42 U.S.C. 1395w–114c(g)(4)) is amended—

(1) in subparagraph (A), in the matter preceding clause (i), by striking and (C) and inserting , (C), and (D);

We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.

(2) by redesignating subparagraphs (D) and (E) as subparagraphs (E) and (F), respectively; and

We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.

(3) by inserting after subparagraph (C) the following:

(D) Phase-in for plasma-derived products.—

(i) In general.— For 2026 and subsequent years, subject to clause (iv), in the case of an applicable drug of a manufacturer that is a plasma-derived product (as defined in clause (ii)), and that is marketed as of August 16, 2022, and dispensed for an applicable beneficiary, the term “discounted price” means the specified plasma-derived product percent (as defined in clause (iii)) of the negotiated price of the applicable drug of the manufacturer.

(ii) Plasma-derived product.— In this subparagraph, the term “plasma-derived product” means an applicable drug that is a biological product that is derived from human whole blood or plasma.

(iii) Specified plasma-derived product percent.— In this subparagraph, the term “specified plasma-derived product percent” means, with respect to a year—

(I) for an applicable drug that is a plasma-derived product dispensed for an applicable beneficiary who has not incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year—

(aa) for 2026, 99 percent;

(bb) for 2027, 98 percent;

(cc) for 2028, 95 percent;

(dd) for 2029, 92 percent; and

(ee) for 2030 and each subsequent year, 90 percent; and

(II) for an applicable drug that is a plasma-derived product dispensed for an applicable beneficiary who has incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year—

(aa) for 2026, 99 percent;

(bb) for 2027, 98 percent;

(cc) for 2028, 95 percent;

(dd) for 2029, 92 percent;

(ee) for 2030, 90 percent;

(ff) for 2031, 85 percent; and

(gg) for 2032 and each subsequent year, 80 percent.

(iv) Limitations.— This subparagraph shall not apply with respect to the following:

(I) Certain drugs dispensed to LIS beneficiaries.— An applicable drug described in subparagraph (B)(i).

(II) Specified small manufacturers.— An applicable drug described in subparagraph (C)(i).

.

We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.